Conceptus, Inc.  

(Public, NASDAQ:CPTS)   Watch this stock  
Find more results for conceptus
0.0000
- Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week     -
Open     -
Vol. 0.00
Mkt cap     -
P/E 0.00
Div/yield     -
EPS 0.28
Shares 32.62M
Beta     -
Inst. own 109%

Key stats and ratios

Q1 (Mar '13) 2012
Net profit margin 5.44% 3.82%
Operating margin 11.77% 9.49%
EBITD margin - 15.63%
Return on average assets 2.97% 2.12%
Return on average equity 4.23% 3.27%
Employees 286 -
CDP Score - -

Address

331 East Evelyn Avenue
MOUNTAIN VIEW, CA 94041
United States - Map
+1-650-9624000 (Phone)
+1-650-9625200 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Conceptus, Inc. designs, develops, markets and promotes solutions in women�s healthcare. The Company�s flagship product is the Essure permanent birth control procedure, which is the non-surgical permanent birth control system. The Essure delivers a soft and flexible insert into a woman�s fallopian tubes, causing a benign tissue in-growth, which blocks the fallopian tubes. Successfully placed Essure inserts and the subsequent tissue growth around, and through the inserts prohibits the egg from traveling through the fallopian tube, preventing conception. In October 2011, the Company acquired from its Dutch distributor certain assets and all distribution rights of the Essure device. In October 2011, it purchased certain assets of Sigma Medical and established a wholly owned subsidiary in the Netherlands, Conceptus B.V. (BV). During the year ended December 31, 2011, approximately 600,000 women worldwide have undergone the Essure procedure.